Navigation Links
Drug TEMODAL and Radiotherapy for brain cancer treatment

Canada Health Government has approved the drug TEMODAL in combination with Radiotherapy for treating patients with glioblastoma multiforme brain cancer. // The drug TEMODAL that contains Temozolomide is produced by Schering-Plough Corporation and is used in treating two forms of brain cancer Glioblastoma multiforme and anaplastic astrocytoma.

Clinical study using the drug TEMODAL was tested on newly diagnosed glioblastoma multiforme patients by researchers from National Cancer Institute, Canada and European organization for Research and Treatment of Cancer and they found the drug to be effective in controlling the growth of malignant cells in the brain, by producing cytotoxic effect on cancer cells and prevents replication and production of cancer cells. Researchers have found on a clinical study on 573 patients that a combination of drug TEMODAL and radiotherapy in brain cancer patients reduces the tumor burden and significantly increases the survival of the cancer patients. The drug has been shown very effective but is found to cause mild side effects of myelosuppression in patients and the researchers have reported the results of their study in the Journal the New England Journal of Medicine.


'"/>




Page: 1

Related medicine news :

1. Radiotherapy helps in colon cancer
2. Link between Obesity and Post-Radiotherapy Outcome in Prostate Cancer Patients
3. Booster Dose Of Radiotherapy Beneficial In Early Breast Cancer
4. Patients Receiving Treatment with Radiotherapy Might trigger Security Alarms
5. Recurrence of bowel cancer cut down by Radiotherapy
6. Radiotherapy Centers in Scotland Undergo Inspection
7. Multi billion-dollar suit filed against cell phone firm for causing brain tumours
8. Two doctors suspended for wrong brain surgery
9. The brain loves a surprise
10. Increase in sugar...decrease in brain function!!!
11. Alcohol shrinks brain
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... 2017 , ... In its ongoing effort to educate consumers ... and published an informational resource that addresses frequently asked questions. , “ ... site’s team of third party administrator (TPA) contributors regularly receives as employers, benefit ...
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin Harper, ... of few medical professionals in the country to sit on the 2017 National Advisory ... in just 2 years Dr. Harper helped propel the clinic from a small start-up ...
(Date:3/28/2017)... ... 28, 2017 , ... AutismOne announced the Board Certified in ... Medicine and available for application on Saturday, May 27, 2017, following Thursday, Friday, ... Springs. , Ed Arranga, president of AutismOne, stated: "Many of the modalities termed ...
(Date:3/28/2017)... ... March 28, 2017 , ... Public relations pros work hard to ... of business channels. , While many results are clear, much of PR is hard ... , When it comes to measurement, firms should always take an all-inclusive approach that ...
(Date:3/28/2017)... ... ... With expansion and efficiency in mind, Patten Seed Company completed relocation of ... opened in Marshallville in 2006, and a bagging and shipping facility has been in ... Patten Seed operations to the Middle Georgia location from their previous home in Lakeland, ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... The global surgical sealants ... of USD 4.5 billion by 2025, according to a ... of injured tissues post operation is a major step ... in 3% to 15% of cases and are considered ... third of postoperative deaths in patients. Surgical sealants and ...
(Date:3/27/2017)... , March 27, 2017 ... better understand Bayer and its partnering interests and activities since ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ... data. The report will be delivered in PDF ...
(Date:3/27/2017)...  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the ... of common stock in an underwritten public offering under ... Securities and Exchange Commission (the "SEC"). The offering is ... be no assurance as to whether or when the ... size or terms of the offering. Cryoport also expects ...
Breaking Medicine Technology: